Malignant lymphoma (disorder)
RiVa
Year Started: 2017
A Phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
-
No restrictions
Associated Data Type |
Procurement Timeframe |
Biomarker datasets |
> 6 months |
Clinical records |
> 6 months |
Followup records |
> 6 months |
Freezer temperature logs |
> 6 months |
Genomic datasets |
> 6 months |
Imaging data |
> 6 months |
Pathology records |
> 6 months |
Physiological/biochemical measurements |
> 6 months |
Treatment records |
> 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
Plasma |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Serum |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Tissue specimen |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
Plasma |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Serum |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Tissue specimen |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
Plasma |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Serum |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Tissue specimen |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type |
Extraction Procedure |
Storage Temperature |
Preservation Type |
Macroscopic Assessment |
% of Sample Set |
Plasma |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Serum |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |
Tissue specimen |
|
-60°C to -85°C |
|
Not applicable |
75% -99% |